Endometrial Cancer Clinical Trial
Official title:
Role of Sex Hormone and Insulin/IGF Axes in Endometrial Cancer Recurrence
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory
may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying the role of biomarkers in endometrial cancer
recurrence in samples from patients with stage II, stage III, or stage IV endometrial
cancer.
OBJECTIVES:
- To investigate the association of endometrioid adenocarcinoma (EA) recurrence with
pre-operative serum levels of insulin, total and free insulin-like growth factor-I
(IGF-I), IGF-II, insulin-like growth factor-binding protein-1 (IGFBP-1) and IGFB-3,
estradiol, estrone, progesterone, and sex hormone-binding globulin (SHBG) in samples
from patients with stage II-IV endometrial cancer evaluated on GOG-0210.
- To study the associations of EA recurrence with pre-treatment tumor expression of
IGF-I, IGF-II, and IGFBP-1 and -3 mRNA in samples from these patients.
- To study the associations of EA recurrence with pre-treatment tumor expression of
insulin receptor, IGF-I receptor, estrogen receptor, and progesterone receptor in
samples from these patients.
- To measure the correlations of serum (protein) and tissue (mRNA) levels of IGF-I,
IGF-II, and IGFBP-1 and -3 from samples of patients with EA and participants without
cancer.
OUTLINE: Banked serum and tumor tissues samples are analyzed for levels of insulin, total
and free insulin-like growth factor (IGF-I), IGF-II, IGFBP-1 and IGFBP-3, estradiol,
estrone, progesterone and sex hormone-binding globulin (SHBG); expression of IGF-I, IGF-II,
IGFBP-1 and IGFBP -3 mRNA; and expression of the insulin receptor, IGF-I receptor, estrogen
receptor, and progesterone receptor by RT-PCR, IHC, and ELISA. Banked non-cancerous
endometrial tissue and fasting serum samples from controls are also analyzed for IGF-I,
IGF-II, IGFBP-1, and IGFBP-3 and compared with the results of endometrial adenocarcinoma
(EA) samples.
Clinical information associated with each EA samples (i.e., age, BMI, performance status,
race, ethnicity, tumor stage, size, histology and grade, surgical compliance and type of
post surgical adjuvant therapy, overall survival, recurrence-free survival, site of first
recurrence, and biomarker values and expression) is also collected.
PROJECTED ACCRUAL: A total of 815 patient specimens and 50 control specimens will be accrued
for this study.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
| Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
| Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
| Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
| Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
| Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
| Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
| Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
| Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
| Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 |